What does this research mean for the field?

Bladder-sparing approaches, particularly trimodal therapy, are effective and suitable alternatives to radical cystectomy for appropriately selected patients with muscle-invasive bladder cancer, offering improved quality of life and low severe toxicity. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the efficacy and safety of bladder-sparing alternatives to radical cystectomy for muscle-invasive bladder cancer.

April 19, 2026

Alternatives to radical cystectomy: a bladder‐sparing approach in appropriately selected patients

Key Points

To evaluate the efficacy and safety of bladder-sparing alternatives to radical cystectomy for muscle-invasive bladder cancer.
Reviewed bladder-sparing treatments like trimodal therapy and TURBT monotherapy.
Assessed QoL outcomes associated with bladder-sparing approaches compared to radical cystectomy.
Analyzed complication rates and treatment-related toxicity in bladder-sparing strategies.
Trimodal therapy shows favorable QoL outcomes, particularly in urinary and sexual function preservation.
Severe adverse events from trimodal therapy occur in less than 10% of patients.
11-16% of patients may eventually require salvage radical cystectomy after bladder-sparing approaches.

Abstract

Radical cystectomy (RC) has historically been the standard treatment for muscle-invasive bladder cancer (MIBC); nonetheless, it is associated with a high morbidity and mortality, with complication rates often exceeding 60%, a relatively high 90-day mortality rate, as well as a significant impact on quality of life (QoL). This substantial burden has generated increasing interest in effective bladder-sparing alternatives. Among these approaches to bladder preservation, trimodal therapy (TMT), comprising maximal transurethral resection of bladder tumour (TURBT) followed by concurrent chemotherapy and radiotherapy (chemoRT) using radiosensitising agents, has become a guideline accepted alternative to RC in appropriately selected patients with MIBC. Additional bladder-sparing strategies, such as TURBT monotherapy or TURBT followed by systemic therapy and surveillance in those patients achieving a complete clinical response, may be alternatives in select settings, although data are limited. Appropriate surveillance after a bladder-sparing approach is paramount to offer timely salvage RC when needed, occurring in approximately 11-16% of contemporary TMT cohorts. QoL outcomes consistently favour TMT over RC, particularly in preserving urinary and sexual function. Severe treatment-related toxicity with TMT is uncommon, with Grade ≥3 adverse events occurring in <10% of cases. In conclusion, bladder-sparing approaches offer a suitable alternative to RC in appropriately selected patients with MIBC, incorporating multidisciplinary care and a commitment to lifelong surveillance.

Mark Helpful

Bookmark

Relay